跳转至内容

Dear Customer:

The current international situation is complex and volatile, and uncertain tariff policies may potentially impact our product prices. Given these uncertainties, we value your understanding regarding order-related matters.

If you decide to place an order during this period, we reserve the right to adjust the price based on the evolving situation. We understand that market changes may cause inconvenience. We will negotiate with you if there’s a significant price fluctuation due to tariff policy changes before the order’s actual delivery, and in such cases we may adjust or cancel the order as necessary.

For important updates on recent policy changes, please click here for more details.

Merck
CN
  • Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE/choroid organ culture.

Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE/choroid organ culture.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2014-07-23)
Alexa Klettner, Muhammed Recber, Johann Roider
摘要

Anti-VEGF treatment is the therapy of choice in age-related macular degeneration and is also applied in diabetic macular edema or retinal vein occlusion. Recently, aflibercept has been approved for therapeutic use. In this study, we investigate the efficacy of aflibercept in comparison with the VEGF-antagonists ranibizumab and bevacizumab in RPE/choroid organ cultures. RPE/choroid organ cultures were prepared from freshly slaughtered pigs' eyes. Organ cultures were treated with 125 μg/ml aflibercept, ranibizumab, or bevacizumab, and the VEGF content of the supernatant was evaluated over the course of 7 days. Additionally, the minimal concentration of VEGF inhibition was evaluated in organ cultures, measured after 6 h of application. Aflibercept was able to completely inhibit VEGF detection for 6 h at a minimal concentration of 0.031 μg/ml, in contrast to bevacizumab (3.9 μg/ml) and ranibizumab (0.244 μg/ml). A statistically significant VEGF inhibition compared to control could be found for aflibercept and ranibizumab down to and including 0.031 μg/ml, while bevacizumab was significantly reduced compared to control down to a concentration of 0.244 μg/ml and again at 0.061 μg/ml. Inhibition of VEGF after a single aflibercept application of 125 μg/ml could be found over the course of 7 days, with some VEGF detectable at the 7th day. In contrast, VEGF was detectable after 72 h of ranibizumab treatment and some VEGF could already be found 12 h after bevacizumab treatment. In conclusion, aflibercept displays a prolonged VEGF inhibition, confirming its effectiveness but also raising concerns about possible side effects of long-term usage.

材料
货号
品牌
产品描述

Sigma-Aldrich
人VEGF-A ELISA试剂盒, for serum, plasma, cell culture supernatants and urine
登录查看公司和协议定价
货号包装规格是否有货价格数量
1 kit
国内现货,预计发货时间 April 21, 2025
详情...
CN¥5,975.44
Sigma-Aldrich
大鼠VEGF ELISA试剂盒, for serum, plasma and cell culture supernatant
登录查看公司和协议定价
货号包装规格是否有货价格数量
1 kit
预计发货时间 September 03, 2025
详情...
新价格,新优惠!
CN¥5,282.92
Sigma-Aldrich
小鼠VEGF ELISA试剂盒, for serum, plasma, cell culture supernatant
登录查看公司和协议定价
货号包装规格是否有货价格数量
1 kit
请联系客服了解存货情况
新价格,新优惠!
CN¥5,282.92
Sigma-Aldrich
人VEGF R3 ELISA试剂盒, for serum, plasma, cell culture supernatant, urine
登录查看公司和协议定价
货号包装规格是否有货价格数量
1 kit
请联系客服了解存货情况
新价格,新优惠!
CN¥5,282.92